Simvastatin to Lower LDL - Quick Reference Sheet
evipedia.ai
← Back

Simvastatin to Lower LDL

Created on 09/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Simvastatin is an inexpensive oral medication from the statin family that lowers low-density lipoprotein cholesterol by slowing the liver's cholesterol production. Reductions grow with dose, and long-running trials link them to fewer heart attacks, strokes and deaths, with the largest gains in higher-risk people. Trade-offs are rare serious muscle problems tied to high doses and interacting drugs, a modest rise in diabetes risk, and possibly dampened fitness gains. (Full Review)

Protocol

Standard dose range
20–40 mg once daily
5–10 mg for low-risk or sensitive individuals; 80 mg reserved for those already tolerating it for 12 months or more
Intensity positioning
Moderate intensity at 20–40 mg
30–49% LDL lowering; required reductions above 45–50% favor combination therapy (e.g., ezetimibe) or a higher-potency statin
Single or split dose
Single daily dose
Splitting offers no advantage; evening dosing is traditional, but morning and evening show no significant LDL difference
Time to effect
Fewer cardiovascular events
About 1 year
Evident after about 1 year of continuous use; benefit grows with duration
Maximum LDL lowering
About 4–6 weeks
LDL cholesterol reaches its maximum reduction
Initial LDL fall
Within 2 weeks
LDL cholesterol falls

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Active liver disease, decompensated cirrhosis (Child-Pugh Class C) or unexplained persistent ALT above 3 times the upper limit of normal
  • Prior statin-induced rhabdomyolysis or immune-mediated necrotizing myopathy
  • Strong CYP3A4 inhibitors (itraconazole, ketoconazole, posaconazole, clarithromycin, erythromycin, HIV protease inhibitors, cobicistat, nefazodone)
  • Gemfibrozil, cyclosporine, danazol
  • SLCO1B1 poor-function genotype (rs4149056 CC)
  • Severe kidney impairment (eGFR below 30 mL/min/1.73 m²) at starting doses above 5 mg
    •
Key Interactions
  • Verapamil, diltiazem, dronedarone (simvastatin capped at 10 mg daily)
  • Amiodarone, amlodipine, ranolazine, lomitapide (simvastatin capped at 20 mg daily)
  • Colchicine; systemic fusidic acid (avoid)
  • Warfarin and digoxin
  • CYP3A4 inducers (rifampin, carbamazepine, efavirenz)
  • Over-the-counter niacin (1 g/day or more)
  • Grapefruit juice (avoid)
  • Red yeast rice
  • St. John's wort
  • Berberine and goldenseal
  • Supplements with additive LDL lowering (plant sterols/stanols, psyllium, bergamot, soluble fiber)
  • Other LDL-lowering interventions (ezetimibe, PCSK9 inhibitors)
    •

Risk & Side Effects

  • High: Muscle symptoms, myopathy and rhabdomyolysis; new-onset diabetes
    •
  • Medium: Liver enzyme elevation and rare liver injury; blunted aerobic fitness gains
    •
  • Low: Hemorrhagic stroke; cognitive complaints; cancer; gastrointestinal adverse events and headache
    •
  • Speculative: Coenzyme Q10 depletion
    •

Monitoring

Marker Target Why
LDL cholesterol Below 70 mg/dL; many longevity practitioners aim below 55 mg/dL Goal measure
ApoB Below 60 mg/dL Counts plaque-forming particles
Non-HDL cholesterol Below 100 mg/dL All plaque-forming cholesterol
Triglycerides Below 100 mg/dL Remnant particle burden
Lipoprotein(a) Below 30 mg/dL (75 nmol/L) Inherited risk that statins do not lower
ALT Below 25–30 U/L Liver safety
CK No established target; track change from own baseline Muscle safety
HbA1c Below 5.4% Diabetes risk
TSH 0.5–2.5 mIU/L Hypothyroidism raises LDL and myopathy risk
eGFR Above 90 mL/min/1.73 m² Dosing and myopathy risk
hs-CRP Below 1 mg/L Residual inflammatory risk
SLCO1B1 genotype Normal function (rs4149056 TT) Myopathy risk and dose ceiling

Cadence: Baseline panel before starting; lipid panel with apoB 4–12 weeks after starting or changing the dose, then every 6–12 months once stable; HbA1c at 3–12 months, then yearly; ALT and CK only with symptoms or after adding an interacting drug; lipoprotein(a) once; optional one-time SLCO1B1 genotyping

Qualitative Assessment

  • Muscle comfort: new aches, cramps or weakness, especially symmetrical thigh or shoulder pain
  • Energy and fatigue: changes in daily energy after starting
  • Exercise capacity: training progress and recovery
  • Cognitive clarity: memory or concentration changes
  • Sleep quality: sleep onset, continuity and dreams
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.